Drug intelligence / Profile preview

CR-101-1

Development stage: Unknown
Lead developer: Currax Pharmaceuticals

Overview

CR-101-1 is an investigational once-daily formulation currently in Phase 1 clinical development for the treatment of obesity. Developed by Currax Pharmaceuticals, a specialty pharmaceutical company focused on metabolic health and smoking cessation, the candidate's specific active ingredients and molecular targets remain undisclosed. It is part of a suite of obesity-focused pipeline programs at Currax, which also includes CR-101-2 and various combination therapies. As of early 2024, the program is in the early stages of clinical testing to evaluate safety and pharmacokinetics.

Beyond the preview

Go deeper on CR-101-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CR-101-1.

Explore the full profile